Citius Oncology (CTOR) Income from Continuing Operations (2023 - 2026)

Citius Oncology's Income from Continuing Operations history runs 4 years deep, the most recent figure standing at 26609695.0 for Q1 2026.

• In Q1 2026, Income from Continuing Operations fell 243.99% year-over-year to 26609695.0; the TTM figure through Mar 2026 stood at 42510376.0 (down 77.1% YoY), while the FY2025 annual figure was 24761369.0, down 17.08% from the prior year.
• Income from Continuing Operations was 26609695.0 for Q1 2026 at Citius Oncology, down from 5534069.0 in the prior quarter.
• In the past five years, Income from Continuing Operations ranged from a high of 147922.0 in Q1 2023 to a low of 26609695.0 in Q1 2026.
• Historically, Income from Continuing Operations has averaged 6000821.92 across 4 years, with a median of 4916101.0 in 2024.
• The sharpest annual moves came in 2024 and 2025: Income from Continuing Operations sank 3168.98% in 2024, then increased 16.9% in 2025.
• A 4-year view of Income from Continuing Operations shows it stood at 4727403.0 in 2023, then sank by 40.86% to 6659205.0 in 2024, then climbed by 16.9% to 5534069.0 in 2025, then plunged by 380.83% to 26609695.0 in 2026.
• The last three Income from Continuing Operations figures came in at 26609695.0 (Q1 2026), 5534069.0 (Q4 2025), and 4996656.0 (Q3 2025), per Business Quant data.